What is the 13F Pro Quality Score for CING?

13F Pro ranks Cingulate Inc. (CING) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CING's current score at https://13fpro.ai/company/CING (free sign-up required for the full ranking).

Where does 13F Pro source CING data?

All Cingulate Inc. fundamentals and ownership data come directly from SEC EDGAR. Cingulate Inc. files with the SEC under CIK 1862150. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CING in?

Cingulate Inc. (CING) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CING research updated on 13F Pro?

CING's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cingulate Inc.(CING)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1862150 CING stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

CING Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Cingulate Inc. (CING), a Healthcare sector company. CING is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Cingulate Inc. reports net income of $-5.9M, free cash flow of $-6.0M. Top institutional holders of CING by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, SUSQUEHANNA INTERNATIONAL GROUP, LLP, RAYMOND JAMES FINANCIAL, based on the most recent SEC filings. CING trades on the Nasdaq exchange and files with the SEC under CIK 1862150. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CING daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cingulate Inc. directly from SEC EDGAR.

✦

Fun facts about Cingulate Inc.

Quirks, history, and lore behind CING — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap U.S. biopharmaceutical company · listed on Nasdaq · focused on developing treatments for central nervous system disorders.
2
The Numbers
A clinical-stage company with no approved products yet, meaning revenue is essentially zero and it runs on capital raises — the classic pre-commercialization burn rate.
3
The History
Founded in the 2010s and built around a novel drug-delivery platform designed to improve on existing stimulant medications used for attention disorders.
4
The Secret
Its proprietary Precision Timed Release technology aims to deliver medication in multiple pulses throughout the day — mimicking how a doctor might ideally time doses by hand.
5
The Lore
Its lead pipeline targets ADHD, and its approach is designed to reduce the peaks and crashes that come with conventional extended-release stimulants — a longtime complaint of patients and parents alike.
6
The Giveaway
A Kansas-based pharma micro-cap chasing FDA approval for its CTx-1301 ADHD drug, trading under a ticker that rhymes with a word meaning to encircle — CING.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-5.9M

Free Cash Flow

Q2 2026

$-6.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-35.6% YoY

$-22.4MFY 2025

FY22 $-17.7MFY23 $-23.5MFY24 $-16.6MFY25 $-22.4M

Operating Income

-27.4% YoY

$-19.9MFY 2025

FY22 $-17.5MFY23 $-22.8MFY24 $-15.6MFY25 $-19.9M

EPS (Diluted)

+59.1% YoY

$-4.44FY 2025

FY22 $-7.34FY23 $-78.00FY24 $-10.86FY25 $-4.44

Total Assets

+1.4% YoY

$15.1MFY 2025

FY22 $11.4MFY23 $3.5MFY24 $14.9MFY25 $15.1M

Op. Cash Flow

+6.5% YoY

$-17.2MFY 2025

FY22 $-15.9MFY23 $-15.0MFY24 $-18.5MFY25 $-17.2M

Free Cash Flow

+6.7% YoY

$-17.4MFY 2025

FY22 $-16.0MFY23 $-15.3MFY24 $-18.7MFY25 $-17.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-22.4M -35.6%	$-16.6M +29.6%	$-23.5M -33.1%	$-17.7M +14.6%	$-20.7M -188.3%	$-7.2M
Operating Income	$-19.9M -27.4%	$-15.6M +31.3%	$-22.8M -30.0%	$-17.5M +15.4%	$-20.7M -191.9%	$-7.1M
EPS (Diluted)	$-4.44 +59.1%	$-10.86 +86.1%	$-78.00 -963.0%	$-7.34	—	—
Total Assets	$15.1M +1.4%	$14.9M +325.7%	$3.5M -69.4%	$11.4M -50.2%	$22.9M +295.4%	$5.8M
Operating Cash Flow	$-17.2M +6.5%	$-18.5M -22.7%	$-15.0M +5.3%	$-15.9M -52.2%	$-10.4M -53.2%	$-6.8M
Free Cash Flow	$-17.4M +6.7%	$-18.7M -22.3%	$-15.3M +4.8%	$-16.0M -42.6%	$-11.2M -55.9%	$-7.2M

Get alerted when CING's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cingulate Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CING

VANGUARD CAPITAL MANAGEMENT LLC
$3.1M570,873 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.2M218,600 sh
RAYMOND JAMES FINANCIAL INC
$912.9K166,898 sh
Chicago Partners Investment Group LLC
$912.0K188,429 sh
Kestra Advisory Services, LLC
$828.7K151,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$791.4K144,636 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$778.4K142,300 sh
RENAISSANCE TECHNOLOGIES LLC
$697.4K127,500 sh
VANGUARD FIDUCIARY TRUST CO
$433.0K79,160 sh
SIMPLEX TRADING, LLC
$379.1K69,300 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$3.1M	570,873
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.2M	218,600
RAYMOND JAMES FINANCIAL INC	$912.9K	166,898
Chicago Partners Investment Group LLC	$912.0K	188,429
Kestra Advisory Services, LLC	$828.7K	151,500
GEODE CAPITAL MANAGEMENT, LLC	$791.4K	144,636
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$778.4K	142,300
RENAISSANCE TECHNOLOGIES LLC	$697.4K	127,500
VANGUARD FIDUCIARY TRUST CO	$433.0K	79,160
SIMPLEX TRADING, LLC	$379.1K	69,300

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CING on your watchlist

Track score changes the day Cingulate Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CING a good stock to buy?

13F Pro's AI-powered analysis of Cingulate Inc. (CING) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CING are available on the CING stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CING is classified as a small company.

Which hedge funds own CING?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CING. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cingulate Inc.'s investment landscape.